Senti Biosciences Inc
Ownership
Ownership Structure
Who owns Senti Biosciences Inc (SNTI)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 38.5% of the shares are freely tradable; institutional investors hold 18.5%.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Nantahala Capital Management, LLC | 2.85 | 888,000 | +0.0 | 06/30/2026 |
| Vanguard Capital Management, LLC | 1.73 | 537,504 | +0.0 | 06/30/2026 |
| Geode Capital Management, LLC | 0.60 | 187,065 | -9.6 | 06/30/2026 |
| Citadel Advisors Llc | 0.34 | 107,100 | +0.0 | 06/30/2026 |
| Vanguard Fiduciary Trust Co | 0.29 | 91,193 | +0.0 | 06/30/2026 |
| Jane Street Group LLC | 0.17 | 52,530 | +0.0 | 06/30/2026 |
| Menlo Ventures Management, L.P. | 0.11 | 35,737 | +0.0 | 06/30/2026 |
| Northern Trust Corp | 0.10 | 32,154 | +91.6 | 06/30/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 1.18 | 368,878 | +0.0 | 09/30/2026 |
| Fidelity Extended Market Index | 0.31 | 95,038 | -0.5 | 08/31/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Insider holdings
| Person | Role | Shares | Value | As of | Type |
|---|---|---|---|---|---|
| Lu Timothy K | CEO | 482,271 | 85,169 $ | Oct 21, 2026 | direct |
| Rajangam Kanya | Pres. & Chief Med. & Dev. Off. | 54,890 | 9,694 $ | Oct 21, 2026 | direct |
Holdings as of each person's most recent SEC Form 4 filing — excluding options and RSUs, which are not shares yet. Holdings may have changed between two filings.
Insiders
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Oct 21, 2026 | Rajangam Kanya | Pres. & Chief Med. & Dev. Off. | Other | 19,953 | 0.00 | – |
| Oct 21, 2026 | Lu Timothy K | CEO | Other | 157,312 | 0.00 | – |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character. View all insider transactions →
Data as of: November 4, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.